Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Acoramidis Modified Release Formulations in Healthy Subjects
NCT04769479Phase 1Completed
- Sponsor
- BridgeBio Pharma
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acoramidis in transthyretin amyloidosis (ATTR), sponsored by BridgeBio Pharma. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the Curve at 72 hours and 1 more. Started Mar 2021; status: completed.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT04769479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04769479.